Logo

REVB

Revelation Biosciences, Inc.

REVB

Revelation Biosciences, Inc. • NASDAQ
$0.96 ▲ 2.46% (+0.02)
Market Cap $5.66 M
52w High $60.48
52w Low $0.83
Dividend Yield 0%
P/E 0.01
Volume 46.60K
Outstanding Shares 5.92M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $1.943M ▼ $-1.907M ▲ 0% $-1.77 ▲ $-1.9M ▲
Q2-2025 $0 $2.461M ▲ $-2.444M ▼ 0% $-7.01 ▼ $-2.454M ▼
Q1-2025 $0 $2.095M ▲ $-2.051M ▼ 0% $-2.11 ▲ $-2.088M ▼
Q4-2024 $0 $1.754M ▼ $-1.726M ▲ 0% $-4.98 ▲ $-1.747M ▲
Q3-2024 $0 $1.797M $-2.242M 0% $-13.38 $-1.789M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $12.708M ▲ $12.856M ▲ $1.855M ▲ $11.002M ▲
Q2-2025 $5.174M ▲ $5.395M ▲ $1.569M ▲ $3.826M ▲
Q1-2025 $3.705M ▼ $3.97M ▼ $1.09M ▼ $2.881M ▼
Q4-2024 $6.499M ▼ $6.622M ▼ $1.914M ▼ $4.708M ▲
Q3-2024 $6.541M $6.74M $4.067M $2.674M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-1.907M ▲ $-1.589M ▲ $0 $9.124M ▲ $7.535M ▲ $-1.589M ▲
Q2-2025 $-2.444M ▼ $-1.919M ▲ $0 $3.389M ▲ $1.469M ▲ $-1.919M ▲
Q1-2025 $-2.051M ▼ $-2.794M ▲ $0 ▼ $0 ▼ $-2.794M ▼ $-2.794M ▲
Q4-2024 $-1.726M ▲ $-3.748M ▲ $17.689K ▲ $3.688M ▼ $-42.034K ▲ $-3.73M ▲
Q3-2024 $-2.242M $-9.257M $-17.688K $3.743M $-5.532M $-9.275M

Five-Year Company Overview

Income Statement

Income Statement Revelation Biosciences is still entirely pre‑revenue. All of its reported years show no meaningful product sales and ongoing operating losses, which is typical for an early clinical‑stage biotech. Losses appear relatively small in absolute terms, suggesting a lean cost base and limited trial activity so far, but the company has never reported a profitable year. The very large swings in reported earnings per share mostly reflect repeated reverse stock splits rather than big changes in the underlying business. Looking ahead, any move into larger clinical trials would likely expand expenses and deepen losses unless partnered funding offsets those costs.

Balance Sheet

Balance Sheet The balance sheet is very light. Assets and cash are small, equity has been thin and somewhat volatile, and there is no financial debt on the books. This suggests the company has kept its structure simple and avoided borrowing, but it also highlights how limited its financial cushion is. Multiple reverse stock splits over the last few years indicate pressure on the share price and a history of equity restructurings, which often go hand in hand with capital raises and dilution. Overall, the balance sheet looks fragile and heavily dependent on continued access to new funding rather than on internally generated capital.

Cash Flow

Cash Flow Cash is consistently flowing out of the business to cover operations, with no offsetting inflows from products. Operating and free cash flow are both negative, and there is essentially no spending on physical assets, which means nearly all cash use is for research, development, and overhead. The burn rate appears modest relative to larger biotechs, but for a company with a small cash base, even modest ongoing outflows matter. Sustainability of the pipeline and trial plans will depend heavily on the company’s ability to raise additional capital or strike partnerships, since current operations do not fund themselves.

Competitive Edge

Competitive Edge Revelation’s competitive story rests on a focused, differentiated platform rather than on scale. The Gemini platform targets the innate immune system in an “upstream” way, which is a distinct approach in kidney disease and infection prevention, where many competitors pursue more traditional or “downstream” targets. The company holds an exclusive license to key intellectual property around its TLR4 agonist, which helps protect any successful products. However, it is competing in areas—acute kidney injury, chronic kidney disease, surgical infections—where very large pharmaceutical companies are also active, with much greater financial and commercial resources. As a small, early‑stage player with no approved products yet, Revelation’s bargaining power is limited, and its competitive position will likely hinge on producing clearly compelling clinical data that can attract partners or acquirers.

Innovation and R&D

Innovation and R&D Innovation is the clear strength of Revelation’s story. The Gemini platform is designed to “reprogram” the innate immune system, with an intravenous formulation aimed at conditions like acute and chronic kidney disease and surgical site infections. Early‑stage data in chronic kidney disease patients suggest the drug can safely reduce inflammatory activity at a cellular level, which is encouraging but still very preliminary. Earlier intranasal programs for viral infections and allergic rhinitis did not meet efficacy goals, showing that the science is high‑risk and not yet fully proven in humans. The company is now concentrating its resources on the intravenous Gemini programs and exploring options for its respiratory diagnostic asset, REVDx‑501. Key watch points are: outcomes of discussions with regulators on the path forward in acute kidney injury, the design and results of larger trials in kidney disease, and whether the company can secure partnerships or non‑dilutive funding to advance these programs.

Summary

Revelation Biosciences is a very early‑stage, pre‑revenue biotech with a narrow but potentially distinctive technology focus. Financially, it operates with a minimal asset base, no debt, recurring losses, and ongoing cash burn, all of which point to continued reliance on external financing and a limited margin for error. Strategically, its value proposition centers on the Gemini platform’s novel immune‑modulating approach in high‑need kidney and infection settings, supported by IP licensing from a respected academic institution. At the same time, previous trial setbacks in other formulations underline the scientific and clinical uncertainty. Overall, this is a classic high‑risk, high‑uncertainty clinical‑stage profile: meaningful upside depends on successful clinical milestones and regulatory progress, while the near‑term reality is one of fragile finances, no commercial products, and dependence on future funding and partnerships.

NEWS

November 20, 2025 · 9:00 AM UTC

Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year

Read more

November 6, 2025 · 4:15 PM UTC

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025

Read more

October 29, 2025 · 9:00 AM UTC

Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date

Read more

October 15, 2025 · 5:00 PM UTC

Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025

Read more

September 11, 2025 · 8:30 AM UTC

Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds

Read more